<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="922">
  <stage>Registered</stage>
  <submitdate>14/10/2005</submitdate>
  <approvaldate>14/10/2005</approvaldate>
  <nctid>NCT00239538</nctid>
  <trial_identification>
    <studytitle>SMOOTH - Blood Pressure Control in Diabetic/Obese Patients</studytitle>
    <scientifictitle>Prospective, Randomized, Open-label, Blinded Endpoint, Forced Titration Study to Compare Telmisartan Combined With HCTZ (80mg/12.5mg), to Valsartan Combined With HCTZ (160mg/12.5mg), for the Control of Mild-to-moderate Hypertension in Obese Patients With Type 2 Diabetes Mellitus Using ABPM.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>502.399</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - telmisartan combined with hydrochlorothiazide (80/12.5 mg)
Treatment: drugs - valsartan combined with hydrochlorothiazide (160/12.5mg)

Treatment: drugs: telmisartan combined with hydrochlorothiazide (80/12.5 mg)


Treatment: drugs: valsartan combined with hydrochlorothiazide (160/12.5mg)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes from baseline in the mean SBP and DBP as measured by ambulatory blood pressure monitoring (ABPM)</outcome>
      <timepoint>10 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes from baseline in the last 6-hour ABPM mean (relative to dose time) pulse pressure.</outcome>
      <timepoint>10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes from baseline in the 24-hour ABPM mean (relative to dose time) for SBP, DBP and pulse pressure.</outcome>
      <timepoint>10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes from baseline in the ABPM mean (relative to clock time) for SBP, DBP, and pulse pressure during the morning, daytime and night time periods of the 24-hour dosing interval.</outcome>
      <timepoint>10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes from baseline in SBP and DBP load during the 24-hour dosing interval.</outcome>
      <timepoint>10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Responder rates based on the 24-hour ABPM mean (relative to dose time) blood pressures defined</outcome>
      <timepoint>10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In-clinic trough cuff blood pressure measures at the end of both a 4-week (Visit 4) treatment period and a 10-week (Visit 6) treatment period.</outcome>
      <timepoint>4 weeks and 10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Responder rates based on the mean seated trough cuff measurements</outcome>
      <timepoint>4 weeks and 10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Metabolic and inflammatory marker changes from baseline</outcome>
      <timepoint>up to 10 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Ability to provide written informed consent.

          2. Hypertension defined as a mean seated DBP of 95-109 (inclusive) mmHg, and/or SBP of
             140-179 (inclusive) mmHg, measured by BpTRU electronic or manual cuff at Visit 2.

          3. 24-hour mean DBP of &gt;= 85 mmHg, and/or SBP = 130 mmHg, measured by ABPM at Visit 3.

          4. 30 years of age or greater.

          5. Ability to stop current antihypertensive therapy and other disallowed medications
             without risk to the patient.

          6. Diagnosis of type-2 diabetes mellitus with HbA1C less than or equal to 10%.

          7. Overweight or obese as defined by a BMI &gt;= 27 kg/m2 in non-Asians and &gt;= 24 kg/m2 in
             Asians.

          8. Negative UPT for females.</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Pre-menopausal women, not surgically sterile or, not nursing/pregnant or are of
             child-bearing potential and will not practice acceptable methods of birth control
             during study.

          2. Night shift workers

          3. Mean sitting SBP &gt;= 180 mmHg or mean sitting DBP &gt;= 110 mmHg during any visit of the
             placebo run-in period.

          4. Known or suspected secondary hypertension. Hepatic and/or renal dysfunction

          5. Fasting serum glucose &gt; 17 mmol/l (or 300 mg/dl) at visit 2

          6. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, patients
             on dialysis or post-renal transplant patients.

          7. Clinically relevant sodium depletion, hypokalaemia or hyperkalaemia.

          8. Uncorrected volume depletion.

          9. Primary aldosteronism.

         10. Hereditary fructose intolerance.

         11. Biliary obstructive disorders (e.g., cholestasis).

         12. Congestive heart failure

         13. Stroke within the past six months.

         14. Documented severe obstructive coronary artery disease.

         15. Myocardial infarction, cardiac surgery or unstable angina within the past three
             months.

         16. PCI (percutaneous coronary intervention) within the past three months or planned
             during trial period.

         17. Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other
             clinically relevant cardiac arrhythmias.

         18. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant
             stenosis of the aortic or mitral valve.

         19. Patients with type-1 diabetes mellitus.

         20. Patients who have previously experienced symptoms of angioedema during ACE or ARB
             treatment.

         21. History of drug or alcohol dependency in past six months.

         22. Chronic administration of any medications known to affect blood pressure, except
             medication allowed by the protocol.

         23. Any investigational drug therapy within the past month.

         24. Known hypersensitivity to any component of the study drug.

         25. Concurrent use of corticosteroids, colestipol or cholestyramine resins.

         26. Any clinical condition which would not allow safe completion of the protocol.

         27. Inability to comply with the protocol.

         28. Any surgery that is, at the time of screening, planned to take place during the study
             period.

         29. History of non-compliance with prescribed medications.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>840</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>Boehringer Ingelheim Investigational Site - Kippa-Ring</hospital>
    <hospital>Emeritus Research - Malvern</hospital>
    <hospital>Boehringer Ingelheim Investigational Site - Prahran</hospital>
    <postcode>4021 - Kippa-Ring</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>3181 - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>BsAs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Coronel Suárez</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Rosario, Sta. Fe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Col. Del Valle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Col. Magdalena de las Salinas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Col. Sección 16, México, D.F.</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara, Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Zapopan, Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to demonstrate that telmisartan 80 mg combined with
      hydrochlorothiazide 12.5 mg (T80/H12.5) is at least as effective and possibly superior to
      valsartan 160 mg combined with hydrochlorothiazide 12.5 mg (V160/H12.5) in lowering mean
      ambulatory systolic blood pressure (SBP) and diastolic blood pressure (DBP) during the last 6
      hours of the 24-hour dosing interval at the end of a 10-week treatment period in
      mild-to-moderate hypertensive, overweight or obese patients with type 2 diabetes mellitus</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00239538</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim Study Coordinator</name>
      <address>B.I. Canada Ltd.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>